Single-cell profiling of environmental enteropathy reveals signatures of epithelial remodeling and immune activation. Read more about Single-cell profiling of environmental enteropathy reveals signatures of epithelial remodeling and immune activation.
Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells. Read more about Small-molecule targeted therapies induce dependence on DNA double-strand break repair in residual tumor cells.
Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates. Read more about Pulmonary microbiome and gene expression signatures differentiate lung function in pediatric hematopoietic cell transplant candidates.
Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas. Read more about Targeting integrated epigenetic and metabolic pathways in lethal childhood PFA ependymomas.
Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19. Read more about Type I interferon autoantibodies are associated with systemic immune alterations in patients with COVID-19.
RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells. Read more about RETRACTED: A subset of PARP inhibitors induces lethal telomere fusion in ALT-dependent tumor cells.
Enhanced Solid Tumor Recognition and T cell Stemness with SynNotch CAR Circuits Read more about Enhanced Solid Tumor Recognition and T cell Stemness with SynNotch CAR Circuits
SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models. Read more about SynNotch CAR circuits enhance solid tumor recognition and promote persistent antitumor activity in mouse models.
SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma. Read more about SynNotch-CAR T cells overcome challenges of specificity, heterogeneity, and persistence in treating glioblastoma.
Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types. Read more about Loss of TGFβ signaling increases alternative end-joining DNA repair that sensitizes to genotoxic therapies across cancer types.
